ERBB2 and neoplasm: One limitation of this study is that recurrence rates may be over estimated for LB, as the prognosis of HER2-positive LB tumours (24% of all LB tumours) would currently be modified by the benefits of Herceptin treatment (which was not used in this study) and an underestimate for LA, as only 44.9% of patients received adjuvant tamoxifen.